Survodutide vs mazdutide: evidence, cost, and legality

Which is better, survodutide or mazdutide?

Mazdutide has more phase 3 evidence, including two active-comparator diabetes trials (DREAMS-2 against dulaglutide and DREAMS-3 against semaglutide), a regulatory approval in China, and a lower adverse event discontinuation rate in GLORY-1. Survodutide's advantage is its biopsy-based MASH phase 2 result. No trial compares them directly, and in the United States both remain trial-only. [1] [2] [3] [4] [5] [6]

How do survodutide and mazdutide compare?

Survodutide and Mazdutide compared by dimension
Dimension	Survodutide	MazdutideFavored
Mechanism [1] [5]	Glucagon analog engineered to also activate the GLP-1 receptor.	Oxyntomodulin analog that activates the GLP-1 and glucagon receptors.
Note: Same receptor pair, different parent molecules and receptor balance.
Phase 3 weight loss [1] [5]	12.2% (3.6 mg) and 13.0% (6.0 mg) versus 5.4% on placebo at 76 weeks (SYNCHRONIZE-1, 725 adults, treatment regimen estimand).	11.0% (4 mg) and 14.0% (6 mg) versus 0.3% gain on placebo at 48 weeks (GLORY-1, 610 Chinese adults).
Note: The placebo arms differ a lot (5.4% loss versus 0.3% gain), so the drug minus placebo gap is wider for mazdutide.
Type 2 diabetes evidence [2] [3] [7]	Phase 2 (413 adults, 16 weeks): HbA1c down up to 1.71 points; weight loss greater than semaglutide 1 mg at 1.8 mg and above.	Phase 3 DREAMS-2 (731 adults): superior to dulaglutide 1.5 mg on HbA1c and weight at 28 weeks. DREAMS-3 (349 adults): superior to semaglutide 1 mg on a combined HbA1c and weight goal (manufacturer topline).
Liver disease evidence [1] [6]	Phase 2 MASH trial (293 adults, biopsy confirmed): improvement without worsening fibrosis in 47% to 62% versus 14% on placebo at 48 weeks.	No biopsy-based MASH trial has reported.
Tolerability [1] [2] [5]	Gastrointestinal symptoms in 80.9% to 89.7% versus 47.9% on placebo in SYNCHRONIZE-1.	Discontinuation for adverse events 1.5% or less in GLORY-1; gastrointestinal events higher than dulaglutide in DREAMS-2.
Regulatory status [4] [8] [9]	Investigational; not approved by any regulator and not eligible for US compounding.	Approved in China (June 2025 weight management, September 2025 type 2 diabetes). Not FDA approved and not eligible for US compounding.
WADA status [4] [10]	Prohibited under section S0 (non-approved substances).	Not named on the list; with approval in China, section S0 may not apply. Confirm with the relevant anti-doping organization.

Evidence grade and regulatory status

Pulled from each peptide’s own record, so it stays in step with the peptide pages.

Survodutide and Mazdutide: grade, status, and cost
Attribute	Survodutide	Mazdutide
Class	Investigational dual agonist of the glucagon and GLP-1 receptors (acylated peptide, once weekly)	Dual agonist of the GLP-1 and glucagon receptors (oxyntomodulin analog, acylated, once weekly)
What it is	Investigational glucagon/GLP-1 dual agonist: 13% weight loss at 76 weeks in phase 3 and strong liver (MASH) data, but not FDA approved.	GLP-1/glucagon dual agonist with 14% weight loss at 48 weeks in a Chinese phase 3 trial and 18% at 16 mg in a US phase 2; not FDA approved.
Evidence	Evidence: Human RCT evidence	Evidence: Human RCT evidence
FDA status	Regulatory: Not eligible for compounding	Regulatory: Not eligible for compounding
Compounding	Not FDA approved and not approved by any other regulator as of the last verification date. Because survodutide is not a component of an approved drug, has no USP monograph, and is not on the 503A bulks list, it cannot lawfully be compounded by 503A pharmacies or 503B outsourcing facilities. Any product sold as survodutide outside a clinical trial is an unapproved drug that has not been evaluated for identity, purity, or dose.	Not FDA approved as of the last verification date. Because mazdutide is not a component of an FDA approved drug, has no USP monograph, and is not on the 503A bulks list, it cannot lawfully be compounded or dispensed in the United States, and any product sold as mazdutide in the US is an unapproved drug. Its development and registration have centered on China, where the national drug regulator approved it for chronic weight management in adults (June 2025) and for type 2 diabetes (September 2025); those approvals do not make it legal to sell or compound in the US.
WADA	WADA: WADA prohibited	WADA: WADA status unclear
Routes	Subcutaneous injection once weekly (clinical trials only)	Subcutaneous injection once weekly
Typical cost	Not available through licensed channels. Products sold as research chemicals are not lawful for human use and are not verified for identity or purity.	Not available through licensed channels in the United States. Products sold as research chemicals are not lawful for human use and are not verified for identity or purity.
Last verified	Sep 27, 2026	Sep 27, 2026

Has survodutide been tested directly against mazdutide?

No published trial has compared survodutide and mazdutide directly. The dimensions above come from separate studies and labels, and cross-trial comparisons are less reliable than a direct trial.

What do survodutide and mazdutide cost?

Typical cost of Survodutide and Mazdutide
Dimension	Survodutide	Mazdutide
Typical cost	Not available through licensed channels. Products sold as research chemicals are not lawful for human use and are not verified for identity or purity.	Not available through licensed channels in the United States. Products sold as research chemicals are not lawful for human use and are not verified for identity or purity.
Price detail	Price index in progress	Price index in progress

Where a price index exists, the range is the cash price per month across branded, compounded, and telehealth channels, without insurance. The cost pages give each channel separately with its sources. Otherwise the typical cost from the peptide record is shown. Legal access depends on your state: see peptide legality by state.

Frequently asked questions

Are survodutide and mazdutide the same kind of drug?

Yes, both activate the GLP-1 and glucagon receptors and are dosed once weekly. Survodutide is built from glucagon, mazdutide from oxyntomodulin. [1] [5]

Which one causes more weight loss?

Their phase 3 results are similar in absolute terms (13.0% at 76 weeks for survodutide 6.0 mg, 14.0% at 48 weeks for mazdutide 6 mg), but mazdutide's placebo group gained weight while survodutide's lost 5.4%, so mazdutide's placebo-adjusted effect was larger. They have not been compared directly. [1] [5]

Which is better for fatty liver disease?

Survodutide has the stronger liver evidence, a biopsy-based phase 2 MASH trial with improvement in up to 62% versus 14% on placebo. Mazdutide has not reported a comparable trial. [6]

Can I get either one in the US?

No lawful path exists outside a clinical trial. Neither is FDA approved or eligible for compounding; mazdutide is approved only in China. [4] [8]

Conditions studied

Fatty liver disease (MASLD and MASH)

From the blog

Peptides for weight loss, ranked by human evidence
Tirzepatide, semaglutide, and liraglutide lead on human trials. Retatrutide is trial-only, and AOD-9604 and 5-amino-1MQ are animal-only. Ranking, legal status, and dated prices.

Sources

Numbered citations above point to these primary sources. PubMed entries link to the indexed abstract.

Cite this page

Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.

APA style: PeptideAgent. (2026, September 22). Survodutide vs mazdutide: evidence, cost, and legality. https://peptideagent.ai/compare/survodutide-vs-mazdutide
HTML link: <a href="https://peptideagent.ai/compare/survodutide-vs-mazdutide">Survodutide vs mazdutide: evidence, cost, and legality</a>, PeptideAgent, updated September 22, 2026.

Survodutide vs mazdutide

The short answer